# India Biobanking Market > India Biobanking Market Research Report: Size, Share, Trend Analysis By Sample Type (Blood Products, Tissues, Cells, Nucleic Acids, Microbiome Samples), By Applications (Research and Development, Clinical Trials, Personalized Medicine, Regenerative Medicine), By End Use (Academic Research Institutions, Biotechnology Companies, Pharmaceutical Companies, Government Organizations) and By Storage Type (Vapor Phase Storage, Liquid Phase Storage, Cryopreservation Storage) - Growth Outlook & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 5.91% - **2024:** $ 3,015.72 Million - **2025:** $ 3,193.95 Million - **2035:** $ 5,668.8 Million - **Key Players:** Thermo Fisher Scientific (US), Qiagen (NL), Illumina (US), Merck KGaA (DE), STEMCELL Technologies (CA), BioLife Sciences (US), ReproCELL (JP), Biobanking Solutions (FI) **Report ID:** MRFR/HC/52639-HCR · **Pages:** 200 · **Author:** Rahul Gotadki · **Last Updated:** February 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/india-biobanking-market-54402 --- ## Market Summary ## **India Biobanking Market Overview** As per MRFR analysis, the India Biobanking Market Size was estimated at 197.2 (USD Million) in 2023. The India Biobanking Market Industry is expected to grow from 205.6(USD Million) in 2024 to 361.2 (USD Million) by 2035. The India Biobanking Market CAGR (growth rate) is expected to be around 5.256% during the forecast period (2025 - 2035). **Key India Biobanking Market Trends Highlighted** There are a number of important trends in the India Biobanking Market that show how it is changing. One big reason is that individualized medicine is becoming more important, which means that a lot of biobanking needs to be done to keep and study biological samples. As chronic diseases become more common in India, the need for biobanks that can help with genomes and biomarkers research and development is expanding.  The National Biopharma Mission and other government programs also aim to improve biotechnological research, which will help the biobanking industry grow even more in the country. There are many chances in the Indian biobanking field, especially now that digital technology are making it easier to keep track of samples and handle data. There are new partnerships between universities and private companies who are trying to set up well-equipped biobanks that can meet the needs of certain types of research. As more and more clinical trials take place in India, there is a lot of room for biorepositories that can supply the biological samples these investigations need.  Recently, there has been a big change in the India Biobanking Market toward creating standardized biobanking procedures and ethical guidelines. This is because more people are becoming aware of how important it is to keep samples safe and get consent from participants. Also, the growth of biobanks that focus on different groups of people is becoming more important for studying the genetic variety in India's population.This is in line with global trends that show the necessity for representative biobanks to make sure that research results apply to a wide range of people, which would improve the overall quality of biomedical research in India. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **India Biobanking Market Drivers** **Growing Prevalence of Genetic Disorders and Chronic Diseases in India** The increasing rate of genetic disorders and chronic diseases such as diabetes, cancer, and cardiovascular ailments is significantly driving the India Biobanking Market Industry. According to data from the Indian Council of Medical Research, approximately 10 million new cases of cancer are reported in India annually, representing an alarming rise in the demand for biobanking.  Organizations like the Tata Memorial Centre are working on various genomics projects aimed at understanding cancer better through biobanks, highlighting the urgent need for biological samples to facilitate research and treatment developments.Additionally, the National Health Mission has noted that diabetes is projected to affect over 134 million individuals in India by 2025, necessitating the collection and storage of biological samples for research purposes. This growing prevalence emphasizes the critical role of biobanks in advancing medical therapies, translating to a significant market potential. **Increasing Investment in Research and Development for Precision Medicine** The rise of precision medicine is a key driver of the India Biobanking Market Industry, fueled by increased investment in Research and Development (R&D) initiatives. The Department of Biotechnology under the Ministry of Science and Technology has launched various programs encouraging the establishment of biobanks to collect and analyze biological samples, particularly for targeted therapies.  Institutions such as the All India Institute of Medical Sciences (AIIMS) are increasingly adopting biobanking practices to enhance their research capabilities.With an estimated increase in funding for translational research to reach up to 10 billion USD by 2025, the demand for biobanks as critical resources for precision medicine is expected to see substantial growth. **Rising Public Awareness and Support for Biobanking Initiatives** Public awareness surrounding health issues and the significance of biobanking is growing, which is aiding the India Biobanking Market Industry. Initiatives led by non-profit organizations and government health agencies to educate the public about the benefits of biobanking are proving effective.  According to a survey conducted by the Ministry of Health and Family Welfare, 78% of Indians believe that biobanks can contribute to better health outcomes through research.The Indian Biobank Association plays a pivotal role in raising awareness about biological resource collections and their importance in enhancing research methodologies, driving public and private investments into biobanking. **India Biobanking Market Segment Insights** **Biobanking Market Sample Type Insights** The India Biobanking Market, especially the Sample Type sector, has a lot of different parts that are important for different scientific uses. As biobanking grows more popular in India, especially for research, clinical trials, and customized treatment, the importance of sample types such blood products, tissues, cells, nucleic acids, and microbiome samples becomes clearer. Blood products are very important since they are the basis for many research and development projects that focus on haematological studies and diagnostics. Tissues are also very important for researchers because they let them learn about how diseases work and test novel drugs.  Cells, including stem cells and immune cells, are very important for regenerative medicine and therapeutic innovations since they provide a lot of information for clinical use. DNA and RNA are examples of nucleic acids that are important for genomics and proteomics research. These studies help make progress in personalized healthcare and precision medicine. Lastly, Microbiome Samples are getting a lot of attention right now because they can help us learn more about human health and disease, especially when it comes to metabolic disorders and gastrointestinal health.In general, these different sorts of samples in the India Biobanking Market segmentation not only help with important scientific research, but they also show that there is room for new ideas in many fields, like as healthcare, pharmaceuticals, and biotechnology.  As customized medicine and tailored therapies become more popular, the demand for these samples is likely to expand a lot. This shows how strong the biobanking ecosystem is in India. The government and private sectors are working together to improve the biobanking infrastructure and encourage collaboration between institutions. This shows that there are more opportunities and growth drivers in the market, making India an emerging hub for biobanking solutions in the global context. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **Biobanking Market Application Insights** The Application segment of the India Biobanking Market plays a crucial role in advancing medical research and innovation in the country. With a growing emphasis on Research and Development, the sector is expected to significantly contribute to scientific advancements and therapeutic discoveries. Clinical Trials within this segment are vital, as they enable the testing of new drugs and therapies, thus fostering a more robust healthcare system. Personalized Medicine is gaining traction in India, driven by a shift towards tailored treatments based on individual genetic profiles, enhancing treatment efficacy while reducing adverse effects. Regenerative Medicine is also pivotal, focusing on regenerating damaged tissues and organs, which aligns with India’s increasing efforts to bolster healthcare services and improve patient outcomes. The overall market is witnessing substantial growth due to increasing investments in biomedical research, enhancement in technological infrastructure, and collaborative efforts between public and private sectors. These factors contribute to an optimistic outlook for the India Biobanking Market, ensuring its critical role in the healthcare ecosystem through innovative applications. **Biobanking Market End Use Insights** The India Biobanking Market has a diverse End Use segmentation, prominently featuring Academic Research Institutions, Biotechnology Companies, Pharmaceutical Companies, and Government Organizations. Academic Research Institutions play a crucial role in advancing scientific studies by enabling access to biological samples for various research purposes, which enhances the region's educational and research capacities. Biotechnology Companies leverage biobanks for the development and innovation of therapeutic solutions, thereby significantly contributing to the sector's growth. Pharmaceutical Companies rely on biobanks for crucial Research and Development processes, including drug discovery and validation, which fosters advancements in healthcare and enhances patient care. Furthermore, Government Organizations support biobanking initiatives as they align with public health policies and help in disease prevention strategies. This collaboration among diverse players creates an ecosystem that drives innovation and supports the overall growth of the India Biobanking Market, which is poised for robust development due to increasing healthcare demands and advancements in biotechnological research.As a result, the sector witnesses growing interest and investment, laying a strong foundation for further advancements and opportunities within this industry in India. **Biobanking Market Storage Type Insights** The Storage Type segment of the India Biobanking Market plays a crucial role in maintaining the integrity of biological samples for Research and Development purposes and other applications. Vapor Phase Storage is significant due to its ability to maintain low temperatures, ensuring the long-term preservation of sensitive biological materials without the risk of contamination. In contrast, Liquid Phase Storage offers advantages in accessibility and sample retrieval, appealing to laboratories requiring frequent access to samples.  Furthermore, Cryopreservation Storage has gained prominence because of its effectiveness in preserving cells, tissues, and other biological specimens through ultra-low temperatures.This technique not only extends the viability of these samples but also has become a preferred choice for various biobanking organizations. As the focus on personalized medicine and advanced therapies grows, the demand for efficient storage solutions across these methods is expected to rise, driven by the need for high-quality biobanked samples. The expanding India Biobanking Market segmentation reflects these dynamics, identifying the importance of optimal storage techniques in supporting scientific advancements and healthcare innovation. **India Biobanking Market Key Players and Competitive Insights** The India Biobanking Market has grown and changed a lot because of improvements in biotechnology, healthcare research, and the growing need for tailored medication. Competitive insights show that this market has a wide range of biobanks that meet different research goals and commercial needs while also taking into account ethical issues related to collecting and storing samples. There are both private and public companies in the market, and they all want to be the best by using new technology, forming strategic relationships, and building strong infrastructure. Biobanking is heavily dependent on research institutions and hospitals, which help researchers work together to get more and different biological samples.  This makes it easier for researchers to study genetics and diseases. As new companies enter the market and existing ones add more services, the competitive landscape keeps changing. This is because biobanks are becoming more important in the healthcare ecosystem. Apollo Hospitals is a major player in the India Biobanking Market because of its large network and good reputation for providing great healthcare. The organization uses its current infrastructure to provide full biobanking solutions that fit with its dedication to cutting-edge research and patient care. Its strengths come from its established healthcare delivery platforms, which make it easy to collect and handle biological samples quickly. Apollo Hospitals uses biobanking in its clinical operations to help with cutting-edge research projects that attempt to improve patient outcomes. This is part of their focus on customized treatment. The firm benefits from its brand recognition and trust, which allows it to make strategic agreements and work with top academic institutions and research groups. This gives it an even stronger competitive edge in the biobanking field. Neuberg diagnoses is another important company in the India Biobanking Market. It is known for its wide range of laboratory services and dedication to improving diagnoses. The business provides a wide range of biobanking services, such as collecting, storing, and analysing samples for both research and clinical purposes. Neuberg Diagnostics has a significant presence in the market thanks to its cutting-edge technology and state-of-the-art labs, which make biobanking procedures of the highest quality possible. It is a popular choice for research collaborations since it places a strong emphasis on quality assurance and following international standards.  The organization has formed a number of strategic agreements and partnerships to improve its biobanking capabilities, which guarantees a consistent supply of biological samples for different projects. Neuberg Diagnostics is also working to grow its presence in the biobanking field. This shows that the company is dedicated to improving healthcare research in India by offering new services and complete biobanking solutions. **Key Companies in the India Biobanking Market Include:** - Apollo Hospitals - Neuberg Diagnostics - Cryobank - Predicine India - GSK India - Tata Medical Center - Bharat Serums and Vaccines - MediFutures - SRL Diagnostic - Dr. Lal PathLabs - Fortis Healthcare - Panacea Biotec - Biocon - StemCyte India - Lifecell International **India Biobanking Market Industry Developments** Recent developments in the India Biobanking Market have been significant, with major players focusing on enhancing their infrastructure and technological capabilities. Apollo Hospitals has announced strategic initiatives to expand its biobanking services, aligning with the growing demand for personalized medicine. Neuberg Diagnostics has been actively investing in state-of-the-art biobanking facilities to support its research endeavors.  In terms of mergers and acquisitions, there have been noteworthy partnerships, such as Cryobank's acquisition of Lifecell International, reported in July 2023, aimed at strengthening their market presence. GSK India has also partnered with various institutions to facilitate the advancement of biobank research, promoting extensive collaboration within the scientific community.  The market valuation of companies like Bharat Serums and Vaccines and Tata Medical Center has seen an upward trend, reflecting a strong commitment to biobanking, which is expected to drive innovation and improve patient outcomes. Significant events from the past couple of years include the regulation changes by the Indian Council of Medical Research in June 2022, which have encouraged biobanking practices, leading to the enhancement of operational standards and ethical guidelines in the sector. **India Biobanking Market Segmentation Insights** **Biobanking Market Sample Type Outlook** - Blood Products - Tissues - Cells - Nucleic Acids - Microbiome Samples **Biobanking Market Application Outlook** - Research and Development - Clinical Trials - Personalized Medicine - Regenerative Medicine **Biobanking Market End Use Outlook** - Academic Research Institutions - Biotechnology Companies - Pharmaceutical Companies - Government Organizations **Biobanking Market Storage Type Outlook** - Vapor Phase Storage - Liquid Phase Storage - Cryopreservation Storage ## Market Drivers ### Supportive Regulatory Framework A supportive regulatory framework is emerging as a key driver for the biobanking market in India. The government is actively working to establish guidelines and policies that facilitate biobanking operations while ensuring ethical standards and participant safety. Recent initiatives aim to streamline the approval processes for biobanking projects, making it easier for institutions to establish and operate biobanks. This regulatory support is crucial for fostering trust among the public and researchers, as it addresses concerns related to data privacy and sample usage. As the regulatory landscape becomes more favorable, it is anticipated that the biobanking market will experience accelerated growth, with more biobanks being established across the country. ### Growing Demand for Precision Medicine The increasing emphasis on precision medicine is a pivotal driver for the biobanking market in India. As healthcare evolves, there is a notable shift towards personalized treatment plans tailored to individual genetic profiles. This trend is supported by advancements in genomics and biotechnology, which facilitate the collection and analysis of biological samples. The biobanking market is projected to witness substantial growth, with estimates suggesting a CAGR of around 15% over the next five years. This growth is fueled by the rising prevalence of chronic diseases and the need for targeted therapies, thereby enhancing the demand for biobanks that can provide high-quality biological specimens. ### Advancements in Biobanking Technologies Technological advancements are transforming the biobanking market in India, enabling more efficient sample collection, storage, and analysis. Innovations such as automated sample processing, advanced cryopreservation techniques, and improved data management systems are enhancing the operational capabilities of biobanks. These technologies not only increase the reliability and integrity of biological samples but also streamline workflows, making biobanks more attractive to researchers. The integration of artificial intelligence and machine learning in biobanking processes is also emerging, potentially revolutionizing how samples are utilized in research. As these technologies continue to evolve, they are likely to drive growth in the biobanking market, attracting more investment and interest from the scientific community. ### Increasing Public Awareness and Participation Public awareness regarding the importance of biobanking is gradually increasing in India, which serves as a crucial driver for the biobanking market. Educational campaigns and outreach programs are fostering a better understanding of how biobanks contribute to medical research and public health. As awareness grows, more individuals are likely to participate in biobanking initiatives, leading to a larger repository of biological samples. This trend is essential for enhancing the diversity and representativeness of biobanks, which can improve research outcomes. The biobanking market is expected to benefit from this increased participation, as it will provide researchers with a broader range of samples for their studies. ### Rising Investment in Research and Development Investment in research and development (R&D) is a significant driver for the biobanking market in India. The government and private sectors are increasingly allocating funds to enhance biobanking infrastructure and capabilities. Reports indicate that R&D expenditure in the healthcare sector has risen to approximately 2.5% of GDP, reflecting a commitment to innovation. This influx of capital is likely to bolster the biobanking market, as it enables the establishment of state-of-the-art facilities and the adoption of advanced technologies. Consequently, this investment is expected to improve the quality and accessibility of biological samples, thereby attracting more researchers and institutions to utilize biobanks. ## Future Outlook The [Biobanking Market](https://www.marketresearchfuture.com/reports/biobanking-market-5967) in India is projected to grow at a 5.91% CAGR from 2025 to 2035, driven by advancements in personalized medicine, increased research funding, and rising demand for biobanked samples. **New opportunities:** - Expansion of biobanking services to include rare disease research. Development of mobile biobanking units for remote sample collection. Partnerships with pharmaceutical companies for drug development using biobanked samples. By 2035, the biobanking market in India is expected to achieve substantial growth and innovation. ## Segment Insights ### By Sample Type: Blood Products (Largest) vs. Nucleic Acids (Fastest-Growing) The sample type segment in the India biobanking market is diverse, with Blood Products commanding the largest share due to their widespread application in diagnostics and therapeutic treatments. Following closely are Tissues and Cells which are crucial for research and regenerative medicine. Nucleic Acids and Microbiome Samples, while smaller in share, are gaining traction as they cater to advancements in genomics and personalized medicine. Growth trends indicate a significant uptick in demand for Nucleic Acids, driven by the increasing focus on precision medicine and genetic research. Similarly, Blood Products remain a staple comprising a massive part of biobanking, though emerging technologies and research are likely to boost Nucleic Acids as a key player. This movement towards precision in medical treatments is expected to drive overall growth in this segment. Blood Products (Dominant) vs. Nucleic Acids (Emerging) Blood Products play a dominant role in the sample type segment, utilized extensively in transfusions, research, and therapeutic procedures. Their established use and reliability make them a cornerstone of biobanking practices. In contrast, Nucleic Acids represent an emerging segment, reflecting the shifting focus towards genetic and molecular research. As advancements in sequencing technologies and the demand for personalized medicine increase, Nucleic Acids are poised to capture a significant market share, fostering innovations in diagnostics and treatment strategies. The interplay between these two segments illustrates the diverse applications within biobanking, highlighting the ongoing evolution driven by scientific progress. ### By Application: Research and Development (Largest) vs. Personalized Medicine (Fastest-Growing) The India biobanking market has seen varied applications with Research and Development holding the largest share, followed closely by Clinical Trials. Personalized Medicine and Regenerative Medicine are emerging trends, capturing increasing interest and investment from stakeholders aiming to leverage biobanked materials for tailored medical solutions. This distribution indicates the pivotal role of research in advancing therapeutic innovations and clinical applications. In recent years, the growth of the India biobanking market has been significantly driven by the need for advanced medical research and personalized healthcare. The expanding biopharmaceutical sector and rising investments in R&D have bolstered Clinical Trials and Personalized Medicine, with a strong thrust from government initiatives and private sectors. Regenerative Medicine is also gaining traction, propelled by advancements in stem cell technologies and tissue engineering, reflecting a broader shift towards innovative medical approaches. Research and Development (Dominant) vs. Regenerative Medicine (Emerging) Research and Development represents the dominant application in the India biobanking market, focusing on utilizing biobanked samples for novel therapeutic discoveries and advancements in science. This sector benefits from robust institutional collaborations and extensive funding, which drive significant projects aimed at translating research findings into viable medical solutions. In contrast, Regenerative Medicine, although still in its emerging phase, showcases considerable potential for growth, driven by developments in cellular therapies and tissue engineering. This application is increasingly recognized for its transformative capabilities in treating chronic diseases and injuries, positioning it as a focal point for future research initiatives and market expansion. Collaborative efforts between researchers and biobanks are essential in harnessing the full potential of both segments. ### By End-use: Pharmaceutical Companies (Largest) vs. Biotechnology Companies (Fastest-Growing) In the India biobanking market, the distribution of market share among the end-use segments reveals that Pharmaceutical Companies hold the largest share, reflecting their critical role in drug development and clinical studies. Following closely, Academic Research Institutions and Biotechnology Companies also contribute significantly, with Government Organizations showing a smaller yet essential presence, emphasizing their support in regulatory and public health sectors. Growth trends indicate that Biotechnology Companies are emerging as the fastest-growing segment within the market, driven by advancements in personalized medicine and increased R&D investments. Conversely, Pharmaceutical Companies continue to dominate the landscape, fueled by ongoing collaborations and the need for vast biobanking resources to enhance drug discovery and development processes. Pharmaceutical Companies (Dominant) vs. Biotechnology Companies (Emerging) Pharmaceutical Companies represent the dominant force in the end-use segment of the India biobanking market, illustrated by their extensive investments in biobanking facilities that enhance drug research and development capabilities. These companies leverage biobanks for vast sample collections that expedite clinical trials and drug validation processes. In contrast, Biotechnology Companies are emerging, showcasing rapid growth as they innovate with cutting-edge technologies. Their agility allows them to adapt quickly to market demands, particularly in personalizing therapies. This segment is characterized by heightened collaboration with academic institutions, which aids in driving forward the research frontiers, ensuring both segments play crucial but distinct roles in the biobanking ecosystem. ### By Storage Type: Vapor Phase Storage (Largest) vs. Cryopreservation Storage (Fastest-Growing) In the India biobanking market, Vapor Phase Storage holds the largest market share among storage types, indicating its established role in preserving biological samples. Liquid Phase Storage also contributes significantly, yet it is the Cryopreservation Storage that is gaining traction, particularly due to advancements in technology and increasing demand for high-throughput processing. The dynamics between these storage types showcase the evolving needs of biobanking facilities as they adapt to more precise preservation techniques. As the interest in personalized medicine and regenerative therapies grows, the demand for Cryopreservation Storage is rapidly increasing, often seen as the fastest-growing storage type in this segment. Factors such as the rising number of biobanks, advancements in storage technology, and government initiatives promoting biobanking practices are accelerating this trend. Moreover, staunch support from research organizations in India is propelling innovations in vapor and liquid phase methodologies, leading to competitive growth trajectories among these storage types. Storage Techniques: Vapor Phase (Dominant) vs. Cryopreservation (Emerging) Vapor Phase Storage is dominant within the India biobanking market due to its efficiency in sample preservation at ultra-low temperatures, minimizing the risk of sample degradation. This technique is particularly favored for long-term storage of valuable biological specimens, ensuring their integrity over extended periods. Conversely, Cryopreservation Storage is emerging as a critical player, driven by technological advancements and increasing applications in reproductive medicine and stem cell research. This method allows cells to remain viable after freezing, making it essential for advancements in personalized therapies. Both storage types are crucial; however, Vapor Phase retains a more established position, while Cryopreservation is positioned for significant growth as the market demand evolves. ## Competitive Benchmarking The biobanking market exhibits a dynamic competitive landscape characterized by rapid advancements in technology and increasing demand for personalized medicine. Key players such as Thermo Fisher Scientific (US), Qiagen (NL), and Illumina (US) are at the forefront, leveraging their extensive portfolios to enhance operational efficiencies and expand their market reach. These companies focus on innovation, with a strong emphasis on developing cutting-edge biobanking solutions that cater to the evolving needs of research institutions and healthcare providers. Their strategies, which include strategic partnerships and regional expansions, collectively shape a competitive environment that is increasingly focused on technological advancement and customer-centric solutions.In terms of business tactics, companies are localizing manufacturing and optimizing supply chains to enhance responsiveness to market demands. The competitive structure of the biobanking market appears moderately fragmented, with several key players exerting influence over various segments. This fragmentation allows for niche players to thrive, while larger companies consolidate their positions through strategic acquisitions and collaborations, thereby enhancing their competitive edge. In October Thermo Fisher Scientific (US) announced a partnership with a leading Indian research institute to develop advanced biobanking solutions tailored for local healthcare needs. This collaboration is expected to enhance the accessibility of biobanking services in India, thereby positioning Thermo Fisher as a key player in the region. The strategic importance of this partnership lies in its potential to drive innovation and improve patient outcomes through localized research initiatives. In September Illumina (US) launched a new genomic sequencing platform specifically designed for biobanking applications. This platform aims to streamline the process of sample analysis, thereby reducing turnaround times and increasing throughput. The introduction of this technology is likely to strengthen Illumina's market position by providing researchers with more efficient tools for genetic analysis, which is crucial for advancing personalized medicine. In August Qiagen (NL) expanded its biobanking services by acquiring a local biorepository in India. This acquisition not only enhances Qiagen's operational capabilities but also allows for greater integration of its products within the Indian market. The strategic move underscores Qiagen's commitment to expanding its footprint in emerging markets, which is essential for sustaining growth in a competitive landscape. As of November current trends in the biobanking market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) into operational processes. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in driving innovation and enhancing service offerings. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on technological innovation, supply chain reliability, and the ability to deliver customized solutions that meet the specific needs of diverse markets. ## Recent News & Developments Recent developments in the India Biobanking Market have been significant, with major players focusing on enhancing their infrastructure and technological capabilities. Apollo Hospitals has announced strategic initiatives to expand its biobanking services, aligning with the growing demand for personalized medicine. Neuberg Diagnostics has been actively investing in state-of-the-art biobanking facilities to support its research endeavors.  In terms of mergers and acquisitions, there have been noteworthy partnerships, such as Cryobank's acquisition of Lifecell International, reported in July 2023, aimed at strengthening their market presence. GSK India has also partnered with various institutions to facilitate the advancement of biobank research, promoting extensive collaboration within the scientific community.  The market valuation of companies like Bharat Serums and Vaccines and Tata Medical Center has seen an upward trend, reflecting a strong commitment to biobanking, which is expected to drive innovation and improve patient outcomes. Significant events from the past couple of years include the regulation changes by the Indian Council of Medical Research in June 2022, which have encouraged biobanking practices, leading to the enhancement of operational standards and ethical guidelines in the sector. ## Report Scope | MARKET SIZE 2024 | 3015.72(USD Million) | | --- | --- | | MARKET SIZE 2025 | 3193.95(USD Million) | | MARKET SIZE 2035 | 5668.8(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 5.91% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Thermo Fisher Scientific (US), Qiagen (NL), Illumina (US), Merck KGaA (DE), STEMCELL Technologies (CA), BioLife Sciences (US), ReproCELL (JP), Biobanking Solutions (FI) | | Segments Covered | Sample Type, Application, End-use, Storage Type | | Key Market Opportunities | Advancements in personalized medicine drive demand for biobanking market innovations and regulatory compliance. | | Key Market Dynamics | Growing demand for personalized medicine drives innovation and competition in the biobanking market. | | Countries Covered | India | ## Frequently Asked Questions **Q: What is the current valuation of the India biobanking market in 2024?** A: The overall market valuation was $3015.72 Million in 2024. **Q: What is the projected market valuation for the India biobanking market by 2035?** A: The projected valuation for 2035 is $5668.8 Million. **Q: What is the expected CAGR for the India biobanking market during the forecast period 2025 - 2035?** A: The expected CAGR for the market during the forecast period 2025 - 2035 is 5.91%. **Q: Which segment had the highest valuation in 2024 within the India biobanking market?** A: In 2024, the 'Pharmaceutical Companies' segment had the highest valuation at $1200.0 Million. **Q: What are the key players in the India biobanking market?** A: Key players include Thermo Fisher Scientific, Qiagen, Illumina, Merck KGaA, and others. **Q: How much is the 'Clinical Trials' application segment valued at in 2024?** A: The 'Clinical Trials' application segment was valued at $800.0 Million in 2024. **Q: What is the valuation range for 'Cryopreservation Storage' in 2024?** A: The valuation range for 'Cryopreservation Storage' was $1515.72 Million to $2668.8 Million in 2024. **Q: Which sample type segment is projected to grow significantly by 2035?** A: The 'Tissues' sample type segment is projected to grow significantly, with a valuation range of $700.0 Million to $1300.0 Million. **Q: What is the valuation of the 'Personalized Medicine' application segment in 2024?** A: The 'Personalized Medicine' application segment was valued at $600.0 Million in 2024. **Q: Which end-use segment is expected to see the highest growth by 2035?** A: The 'Pharmaceutical Companies' end-use segment is expected to see the highest growth, with a projected valuation of $2500.0 Million by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/india-biobanking-market-54402*